Replies to post #8089 on Mind Medicine (MindMed) Inc (MNMD)

[DarthYoda]

I was looking at the text of the HALT bill, and it looks like it will provide companies that do not currently have licenses to research schedule 1 or 2 substances in the U.S. with a way to begin doing so pretty quickly. The same text is in both the House and Senate versions...

“(B) RESEARCHER WITHOUT A CURRENT SCHEDULE I OR II RESEARCH REGISTRATION.—

“(i) IN GENERAL.—If a practitioner is not registered to conduct research with a controlled substance in schedule I or II, the practitioner may send a notice to the Attorney General containing the information listed in subparagraph (A)(i), with respect to each substance with which the practitioner will conduct the research.

“(ii) ATTORNEY GENERAL ACTION.—The Attorney General shall—

“(I) treat notice received under clause (i) as a sufficient application for a research registration; and

“(II) not later than 45 days of receiving such a notice that contains all information required under subparagraph (A)(i)—

“(aa) register the applicant; or

“(bb) serve an order to show cause upon the applicant in accordance with section 304(c).

https://www.congress.gov/bill/117th-congress/house-bill/6184/text
https://www.congress.gov/bill/117th-congress/senate-bill/3336/text

[DarthYoda]

Simply put, the Feds have to pass the bill before the end of the year or fentanyl will no longer be a schedule 1 substance(expires Dec 31 2022) and I haven't seen any competing bills yet. So, if/when psychedelics become easier to research and manufacture in the U.S., will MNMD do more research here?